160977-92-4 Usage
General Description
N-FMOC-4-(methylamino)benzoic acid is a chemical compound commonly used in organic synthesis and peptide chemistry. It belongs to the family of FMOC-protected amino acids and is often employed as a building block in the preparation of peptide derivatives. N-FMOC-4-(methylamino)benzoic acid is known for its ability to introduce a methylamino group into peptide chains, making it a valuable tool in the design and synthesis of peptide-based drugs and bioactive molecules. Additionally, it is often used as a precursor in the preparation of fluorescent probes and labels for biochemical and biophysical studies. Due to its versatile applications, N-FMOC-4-(methylamino)benzoic acid is widely utilized in the pharmaceutical, biotechnology, and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 160977-92-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,9,7 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 160977-92:
(8*1)+(7*6)+(6*0)+(5*9)+(4*7)+(3*7)+(2*9)+(1*2)=164
164 % 10 = 4
So 160977-92-4 is a valid CAS Registry Number.
160977-92-4Relevant articles and documents
COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Paragraph 0889-0892, (2016/11/14)
Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.
